A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

BACKGROUND The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma. METHODS Galunisertib (300 mg/day) was given orally 14 days on/14 days off (intermittent dosing). Lomustine was given as approved. Patients were randomized in a 2:1:1 ratio to galunisertib + lomustine, galunisertib monotherapy, or placebo + lomustine. The primary objective was overall survival (OS); secondary objectives were safety, pharmacokinetics (PKs), and antitumor activity. RESULTS One hundred fifty-eight patients were randomized: galunisertib + lomustine (N = 79), galunisertib (N = 39), and placebo + lomustine (N = 40). Baseline characteristics were: male (64.6%), white (75.3%), median age 58 years, ECOG performance status (PS) 1 (63.3%), and primary glioblastoma (93.7%). The PKs of galunisertib were not altered with lomustine, and galunisertib had a median half-life of ∼8 hours. Median OS in months (95% credible interval [CrI]) for galunisertib + lomustine was 6.7 (range: 5.3-8.5), 8.0 (range: 5.7-11.7) for galunisertib alone, and 7.5 (range: 5.6-10.3) for placebo + lomustine. There was no difference in OS for patients treated with galunisertib + lomustine compared with placebo + lomustine [P (HR < 1) = 26%]. Median progression-free survival of ∼2 months was observed in all 3 arms. Among 8 patients with IDH1 mutation, 7 patients were treated with galunisertib (monotherapy or with lomustine); OS ranged from 4 to 17 months. Patients treated with galunisertib alone had fewer drug-related grade 3/4 adverse events (n = 34) compared with lomustine-treated patients (10% vs 26%). Baseline PS, post-discontinuation of bevacizumab, tumor size, and baseline levels of MDC/CCL22 were correlated with OS. CONCLUSIONS Galunisertib + lomustine failed to demonstrate improved OS relative to placebo + lomustine. Efficacy outcomes were similar in all 3 arms. CLINICAL TRIAL REGISTRATION NCT01582269, ClinicalTrials.gov.

[1]  R. Stupp,et al.  LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL , 2015 .

[2]  K. Kelsey,et al.  Serum macrophage‐derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time , 2015, International journal of cancer.

[3]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[4]  J. Baselga,et al.  Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer , 2014, Investigational New Drugs.

[5]  J. Baselga,et al.  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.

[6]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Ivelina Gueorguieva,et al.  Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. , 2014, British journal of clinical pharmacology.

[8]  G. Giannelli,et al.  O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD , 2014 .

[9]  S. Grossman,et al.  The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme , 2013, Journal of Neuro-Oncology.

[10]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test--Revised , 2013 .

[11]  Gelareh Zadeh,et al.  Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies , 2012, Archivum Immunologiae et Therapiae Experimentalis.

[12]  F. Hodi,et al.  Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.

[13]  J. Graff,et al.  Abstract C201: The combination of the small molecule TGFβR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. , 2011 .

[14]  M. Preusser,et al.  IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, Clinical neuropathology.

[15]  T. Mikkelsen,et al.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[16]  S. Gautam,et al.  Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[18]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Damian McEntegart,et al.  Randomization by minimization for unbalanced treatment allocation , 2009, Statistics in medicine.

[20]  M. Weller,et al.  Modulation of TGF‐β activity by latent TGF‐β‐binding protein 1 in human malignant glioma cells , 2009, International journal of cancer.

[21]  P. Oefner,et al.  Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. , 2009, Neuro-oncology.

[22]  E. Petricoin,et al.  Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology , 2009, Journal of Translational Medicine.

[23]  David García-Dorado,et al.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.

[24]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[25]  T. Guzzo,et al.  Ongoing Clinical Trials. , 2010, Digestive surgery.

[26]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[27]  M. Weller,et al.  Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. , 2007, Neuro-oncology.

[28]  Alejandra Bruna,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[29]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[30]  M. Gilbert,et al.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) , 2006, Journal of Neuro-Oncology.

[31]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[32]  P. Brown,et al.  Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Sailer,et al.  Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. , 2006, Journal of neuro-oncology.

[34]  M. Sailer,et al.  Increased concentrations of transforming growth factor β1 and β2 in the plasma of patients with glioblastoma , 2006, Journal of Neuro-Oncology.

[35]  B. Mishra,et al.  TGF-β, Neuronal Stem Cells and Glioblastoma , 2005, Oncogene.

[36]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[37]  R. Stupp,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[39]  A. Kanner,et al.  Serum S100β , 2003, Cancer.

[40]  P. Loke,et al.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Weller,et al.  Molecular determinants of glioma cell migration and invasion. , 2001, Journal of neurosurgery.

[42]  A. Mantovani,et al.  Macrophage‐derived chemokine (MDC) , 2000, Journal of leukocyte biology.

[43]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test—Revised: Normative data and analysis of inter-form and test–retest reliability. , 1998 .

[44]  H. Levin,et al.  Benton Controlled Oral Word Association Test: reliability and updated norms. , 1996, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[45]  R. Reitan.  Trail Making Test: Manual for Administration and Scoring , 1992 .